Intrexon | XON - Selling And Administration Expenses

Stock Price
4.13
Daily Change
0.17 4.29%
Monthly
33.23%
Yearly
175.33%
Q2 Forecast
4.04

Intrexon reported $10.31M in Selling and Administration Expenses for its fiscal quarter ending in June of 2024.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Alaunos Therapeutics USD 585K 84K Sep/2025
Amgen USD 1.94B 237M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
MacroGenics USD 7.94M 1.96M Dec/2025
MannKind USD 29.09M 2.53M Sep/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
Veracyte USD 43.31M 8.43M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025